The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under scrutiny amid concerns about efficacy and safety.
Anita T. Shaffer
Advertisement
Articles by Anita T. Shaffer
Patients with lung cancer who participated in a Web-based system for reporting and tracking their symptoms achieved dramatic gains in survival compared with individuals who were followed with typical protocols, according to a study presented at the annual meeting of the American Society of Clinical Oncology.
A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer type aims to simultaneously test the efficacy of more than 20 drugs.
Advertisement
Latest Updated Articles
- Web App Boosts Survival for Lung Cancer Patients
July 22nd 2016
- Sledge Expects 'Big Data' to Generate Big Changes
June 20th 2013
- Early Results Robust for New Immunotherapy Agent
August 23rd 2013
- More Evidence for 10 Years of Tamoxifen in ER+ Breast Cancer
August 23rd 2013
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5